BioCentury | Mar 4, 2002
Company News

Imperial Cancer Research Fund other research news

...fibroids and FH activity was reduced in lymphoblastoid cells from patients with leiomyomatosis (uterine fibroids). Imperial Cancer Research Fund...
BioCentury | Feb 25, 2002
Finance

Ebb & Flow

...a market cap of £22 million ($31 million). Investors included Leventis Holding; Abbott (ABT); the Imperial Cancer Research Fund...
BioCentury | Feb 22, 2002
Financial News

Antisoma raises L23.7 million

...35% discount to ASM's Thursday close at 31p. Investors included Leventis Holding; Abbott (ABT); the Imperial Cancer Research Fund...
BioCentury | Sep 4, 2001
Company News

Imperial Cancer Research Fund other research news

...prone to develop intestinal adenomas. Progeny of these crossed mice developed intestinal adenomas overexpressing CEA. Imperial Cancer Research Fund...
BioCentury | Mar 20, 2000
Company News

Antisoma, Imperial Cancer Research Fund deal

...Phase II studies in the first half of 2001. Antisoma plc (LSE:ASM; EASD:ASOM), London, U.K. Imperial Cancer Research Fund...
BioCentury | Mar 16, 2000
Company News

Antisoma acquires cancer compound

...option to acquire Therex huHMFG1 , a humanized monoclonal antibody to treat cancer, from the Imperial Cancer Research Fund...
BioCentury | May 17, 1999
Company News

Xenova scientific advisory board update

...Cancer Research Unit at the University of Newcastle Upon Tyne; Adrian Harris, director of the Imperial Cancer Research Fund...
BioCentury | Feb 8, 1999
Company News

Hyseq Inc., Imperial Cancer Research Technology Ltd. deal

...HYSQ obtained exclusive rights to ectoapyrase anticlotting agents from Imperial, a subsidiary of the Imperial Cancer Research Fund. The...
BioCentury | Aug 3, 1998
Clinical News

Breast cancer diagnostic system: Approved in Europe

Imperial Cancer Research Fund (London, U.K.) researchers and colleagues published in The Lancet the ability of BZET's Biofield Diagnostic System, which uses skin surface electropotential measurements, to discriminate between breast cancer and benign lesions as...
BioCentury | May 26, 1998
Company News

Lyon Bioinformatics Center, Glaxo Wellcome, The Imperial Cancer Research Fund, Silicon Graphics Inc., The Swiss Institute of Bioinformatics deal

...analysis and software components. Lyon Bioinformatics Center, Lyon, France Glaxo Wellcome plc, London, U.K. The Imperial Cancer Research Fund...
Items per page:
1 - 10 of 18
BioCentury | Mar 4, 2002
Company News

Imperial Cancer Research Fund other research news

...fibroids and FH activity was reduced in lymphoblastoid cells from patients with leiomyomatosis (uterine fibroids). Imperial Cancer Research Fund...
BioCentury | Feb 25, 2002
Finance

Ebb & Flow

...a market cap of £22 million ($31 million). Investors included Leventis Holding; Abbott (ABT); the Imperial Cancer Research Fund...
BioCentury | Feb 22, 2002
Financial News

Antisoma raises L23.7 million

...35% discount to ASM's Thursday close at 31p. Investors included Leventis Holding; Abbott (ABT); the Imperial Cancer Research Fund...
BioCentury | Sep 4, 2001
Company News

Imperial Cancer Research Fund other research news

...prone to develop intestinal adenomas. Progeny of these crossed mice developed intestinal adenomas overexpressing CEA. Imperial Cancer Research Fund...
BioCentury | Mar 20, 2000
Company News

Antisoma, Imperial Cancer Research Fund deal

...Phase II studies in the first half of 2001. Antisoma plc (LSE:ASM; EASD:ASOM), London, U.K. Imperial Cancer Research Fund...
BioCentury | Mar 16, 2000
Company News

Antisoma acquires cancer compound

...option to acquire Therex huHMFG1 , a humanized monoclonal antibody to treat cancer, from the Imperial Cancer Research Fund...
BioCentury | May 17, 1999
Company News

Xenova scientific advisory board update

...Cancer Research Unit at the University of Newcastle Upon Tyne; Adrian Harris, director of the Imperial Cancer Research Fund...
BioCentury | Feb 8, 1999
Company News

Hyseq Inc., Imperial Cancer Research Technology Ltd. deal

...HYSQ obtained exclusive rights to ectoapyrase anticlotting agents from Imperial, a subsidiary of the Imperial Cancer Research Fund. The...
BioCentury | Aug 3, 1998
Clinical News

Breast cancer diagnostic system: Approved in Europe

Imperial Cancer Research Fund (London, U.K.) researchers and colleagues published in The Lancet the ability of BZET's Biofield Diagnostic System, which uses skin surface electropotential measurements, to discriminate between breast cancer and benign lesions as...
BioCentury | May 26, 1998
Company News

Lyon Bioinformatics Center, Glaxo Wellcome, The Imperial Cancer Research Fund, Silicon Graphics Inc., The Swiss Institute of Bioinformatics deal

...analysis and software components. Lyon Bioinformatics Center, Lyon, France Glaxo Wellcome plc, London, U.K. The Imperial Cancer Research Fund...
Items per page:
1 - 10 of 18